Clinical Trial

Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Palmoplantar pustulosis (PPP) is a rare, chronic inflammatory skin disease primarily affecting the palms and soles. Currently, no treatment is specifically approved for PPP globally. This study aims to evaluate the efficacy and safety of tofacitinib combined with imatinib in patients with moderate-to-severe PPP.
Protocol Amendment History 3 changes
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
notable Primary completion pushed: 2028-04-01 -> 2028-08-01 2026-08-04
minor Completion pushed: 2028-12-30 -> 2030-12-30 2026-08-04
Trial Details
NCT Number NCT07530367
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Palmoplantar Pustulosis (PPP)
Enrollment 135 participants
Start Date 2026-08-01
Primary Completion 2028-08-01 (estimated)
Study Completion 2030-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-03